ConductScience.org, home

Library / Trial comparisons

Flublok Quadrivalent Influenza Vaccine vs Inactivated Influenza Vaccine: serious adverse events

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

Measures 6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNoteSource
Risk in group 10.03350.02850.0393wilsonClinicalTrials.gov
Risk in group 20.03040.02570.0359wilsonClinicalTrials.gov
Risk difference, group 1 minus group 20.00312-0.004320.0106newcombe hybrid scoreClinicalTrials.gov
Risk ratio, group 1 over group 21.10.8741.39logClinicalTrials.gov
Odds ratio, group 1 over group 21.110.871.41logClinicalTrials.gov
Number needed to harm, for one more participant with a serious adverse event on Flublok Quadrivalent Influenza Vaccine than on Inactivated Influenza Vaccine321from the risk difference intervalthe interval includes no differenceClinicalTrials.gov

Groups 2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov codeSource
Group 1Flublok Quadrivalent Influenza Vaccine
Intramuscular injection of vaccine containing 4 x 45µg (180µg total) of each recombinant hemagglutinin (rHA) derived from influenza A/H1N1 and A/H3N2 and two lineages of influenza B viruses identified for the season in which the trial is conducted in a total volume of 0.5 mL~Flublok Quadrivalent Influenza Vaccine: Intramuscular injection of vaccine
1454,328EG000ClinicalTrials.gov
Group 2Inactivated Influenza Vaccine
Intramuscular injection of vaccine contains 4 x 15µg (60µg total) of HA derived from the same influenza A/H1N1 and A/H3N2 and influenza B strains in a total volume of 0.5mL.~Inactivated Influenza Vaccine: Intramuscular injection of vaccine
1324,344EG001ClinicalTrials.gov

Harm 2

FieldValueSource
What it countsTotal, serious adverse eventsClinicalTrials.gov
Time frameFrom time vaccination until the end of the influenza season (~6 months).ClinicalTrials.gov

Trial 8

FieldValueSource
TitleProtective Efficacy of Flublok® Quadrivalent Versus Licensed Inactivated Influenza Vaccine in Adults ≥50 Years of AgeClinicalTrials.gov
NCT numberNCT02285998ClinicalTrials.gov
PhasesPHASE3ClinicalTrials.gov
ConditionsInfluenzaClinicalTrials.gov
InterventionsFlublok Quadrivalent Influenza Vaccine, Inactivated Influenza VaccineClinicalTrials.gov
Lead sponsorProtein Sciences CorporationClinicalTrials.gov
Results first posted2016-10-04ClinicalTrials.gov
Results on ClinicalTrials.govhttps://clinicaltrials.gov/study/NCT02285998?tab=resultsClinicalTrials.gov

Source 4

FieldValueSource
Releasetrial-comparisons-2026-03-23-0.1.0ClinicalTrials.gov
Release manifest SHA-256f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57ClinicalTrials.gov
AACT copy2026-03-23ClinicalTrials.gov
Tables readoutcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquetClinicalTrials.gov

The same record as JSON

Release trial-comparisons-2026-03-23-0.1.0

ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.